JPMorgan Reports 5.1% Passive Stake In Rhythm Pharmaceuticals, 3,563,667 Shares
A Schedule 13G lists the holdings across six J.P. Morgan units, with the filer classed as a parent holding company.
JPMorgan Chase holds 3,563,667 shares of Rhythm Pharmaceuticals, or 5.1% of the class, according to a Schedule 13G filed Tuesday. The form is a passive ownership disclosure, and it lists September 30 as the date of the event.
What the Schedule 13G says
The 5.1% is measured on the cover-page basis, which counts any warrants, options or convertibles the holder could exercise within 60 days in both the holding and the share base.
JPMorgan reports sole voting power over 3,358,216 shares and shared voting power over one share. It reports sole dispositive power, meaning the power to sell, over 3,560,983 shares. The filing classes JPMorgan Chase as a parent holding company.
The shares sit across six units named in the filing: J.P. Morgan Trust Company of Delaware, J.P. Morgan Securities, JPMorgan Chase Bank, JPMorgan Asset Management (UK), J.P. Morgan Investment Management and J.P. Morgan Wealth Management Solutions.
What it changes
Nothing about control. In the certification, JPMorgan says that, to the best of its knowledge and belief, the shares were acquired and are held in the ordinary course of business, not to change or influence control of Rhythm.
For holders, the filing adds a new reportable owner above the 5% line. Rhythm's market cap was $6.2 billion as of the original report on Tuesday at 2:07 p.m. ET.
The filing lists Rhythm's address as 222 Berkeley Street in Boston and JPMorgan's as 270 Park Avenue in New York.
Sources
- SCHEDULE 13G — JPMORGAN CHASE & CO. re: RHYTHM PHARMACEUTICALS, INC. (RYTM) — SEC EDGAR
- Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know — Yahoo Finance
- How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Progress In Prader-Willi And Genetically Defined Obesity Therapies — Yahoo Finance